Stat, the health publication of the Boston Globe, reports that the percentage of drug trials which made it to the market was 11 percent last year, the highest percentage in a long time.
More judicious use of resources resulted in higher quality product pipelines which, in turn, could account for the improved showings in clinical trials. The larger proportion of failing compounds in Phase 1, or early-stage trials, may indicate that companies are running more thorough evaluations and doing so sooner. “Basically, the industry is learning how to fail earlier,” said Moller. “And that’s a good thing.”